BR112017011538A2 - combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) - Google Patents

combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)

Info

Publication number
BR112017011538A2
BR112017011538A2 BR112017011538A BR112017011538A BR112017011538A2 BR 112017011538 A2 BR112017011538 A2 BR 112017011538A2 BR 112017011538 A BR112017011538 A BR 112017011538A BR 112017011538 A BR112017011538 A BR 112017011538A BR 112017011538 A2 BR112017011538 A2 BR 112017011538A2
Authority
BR
Brazil
Prior art keywords
antibodies
combination
myeloma
treat cancer
enhancing
Prior art date
Application number
BR112017011538A
Other languages
English (en)
Inventor
Darron Robbins Michael
F. Graziano Robert
BEZMAN Natalie
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112017011538A2 publication Critical patent/BR112017011538A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção descrita aqui, neste requerimento de patente, se refere a regimes de dosagens terapêuticas e combinações dos mesmos para uso no reforço da eficácia terapêutica de anticorpos anti-cs1 em combinação com um anticorpo antimorte programada-1 (pd-1).
BR112017011538A 2014-12-04 2015-12-03 combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) BR112017011538A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087489P 2014-12-04 2014-12-04
PCT/US2015/063585 WO2016090070A1 (en) 2014-12-04 2015-12-03 Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)

Publications (1)

Publication Number Publication Date
BR112017011538A2 true BR112017011538A2 (pt) 2018-03-13

Family

ID=55022696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011538A BR112017011538A2 (pt) 2014-12-04 2015-12-03 combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)

Country Status (13)

Country Link
US (1) US20170355768A1 (pt)
EP (1) EP3227335A1 (pt)
JP (1) JP2017537927A (pt)
KR (1) KR20170088984A (pt)
CN (1) CN107249632A (pt)
AU (1) AU2015358462A1 (pt)
BR (1) BR112017011538A2 (pt)
CA (1) CA2969665A1 (pt)
EA (1) EA201791049A1 (pt)
IL (1) IL252535A0 (pt)
MX (1) MX2017007097A (pt)
SG (1) SG11201704343SA (pt)
WO (1) WO2016090070A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125884A (zh) 2010-12-17 2020-12-25 诺华股份有限公司 制备嘧啶-2,4-二胺二盐酸盐的方法
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
AU2017353852A1 (en) * 2016-11-02 2019-05-23 Apexigen, Inc. Anti-CD40 antibodies in combination and methods of use
US20210155691A1 (en) * 2018-04-16 2021-05-27 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
BR0008379A (pt) 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
US7842293B2 (en) 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
CN101686971B (zh) 2006-08-07 2013-09-11 艾伯特生物治疗学公司 用于治疗多发性骨髓瘤的药物产品及其用途
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
US20130052158A1 (en) 2009-10-30 2013-02-28 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
EP3227335A1 (en) 2017-10-11
MX2017007097A (es) 2017-09-05
IL252535A0 (en) 2017-07-31
SG11201704343SA (en) 2017-06-29
EA201791049A1 (ru) 2017-10-31
CN107249632A (zh) 2017-10-13
KR20170088984A (ko) 2017-08-02
CA2969665A1 (en) 2016-06-09
US20170355768A1 (en) 2017-12-14
WO2016090070A1 (en) 2016-06-09
AU2015358462A1 (en) 2017-07-27
JP2017537927A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
GT201700102A (es) Conjugados de anticuerpo-fármaco
CO2017008804A2 (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
PH12016501411B1 (en) Bifunctional cytotoxic agents
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
BR112016003394A2 (pt) usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MA40612A (fr) Nouveaux anticorps anti-mfi2 et méthodes d'utilisation
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
BR112017002433A2 (pt) anticorpos anticeramida
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.